The investigators hypothesized that treatment with oral GABA, or a combination of GABA/GAD65-alum, would halt or slow the progression of new onset type 1 diabetes (T1DM) by some/all of the following mechanisms: 1) increasing endogenous insulin secretion, 2) suppression of glucagon release, 3) dampening the T-cell mediated autoimmune process. Here, GCG is linked to type 1 diabetes mellitus.